Results

Total Results: 2,336 records

Showing results for "responses".

841. Data-Points-6-Maps (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points-6-maps.pdf
     August 22, 2011 - Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006 * Small cell = less than 11. Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Popul…

842. Disposition of Comments for Screening of Methicillin-Resistant Staphylococcus Aureus (MRSA) (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/mrsa-screening-2010_disposition-comments.pdf
     January 01, 2010 - Comments on draft reviews and the authors’ responses to the comments are posted for public viewing on … The tables below include the responses by the authors of the review to each comment that was submitted … The responses to comments in this disposition report are those of the authors, who are responsible for

843. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/treatment-resistant-depression_disposition-comments.pdf
     September 01, 2011 - Comments on draft reviews and the authors’ responses to the comments are posted for public viewing … The tables below include the responses by the authors of the review to each comment that was submitted … The responses to comments in this disposition report are those of the authors, who are responsible … This study suggests that VNS has a slow onset of response, but that responses are durable, and that

844. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cancer-anemia-update_research-protocol.pdf
     June 16, 2010 - A summary of relevant comments and our responses follow each key question; general comments applying … to all key questions and responses are listed after the last key question. … events including those related to red blood cell transfusion Intermediate outcomes: • hematologic responses

845. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/devdelays_adhd_autism_hi_impact.pdf
     January 01, 2012 - The relationship between autonomic reactivity and behavioral responses to auditory stimulation in high-functioning … $2,000. 4 In 2009, Chang investigated the relationship between autonomic reactivity and behavior responses … reasonable, as one put it, that “clinicians are currently able to track through an EEG or an EKG various responses … an additional resource tool for treatment in the medical diagnostic process by evaluating galvanic responses … Autonomic and behavioral responses of children with autism to auditory stimulation.

846. Disposition of Comments for Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer: An Update of a 2008 Systematic Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer-therapies-update_disposition-comments.pdf
     December 16, 2014 - Comments on draft reviews and the authors’ responses to the comments are posted for public viewing on … The tables below include the responses by the authors of the review to each comment that was submitted … The responses to comments in this disposition report are those of the authors, who are responsible for

847. McCullough (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/mccullough.pdf
     January 01, 2011 - management: clinical ethical tool for responsibly managing uncertainty about plan of care o Candor-­‐based responses

848. Template for Reports Developed (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/c-difficile-future_research.pdf
     October 26, 2012 - Template for Reports Developed Future Research Needs Paper Number 17 Future Research Needs for Prevention and Treatment of Clostridium difficile Infection Future Research Needs Paper Number 17 Future Research Needs for Prevention and Treatment of Clostridium difficile Infection Identification o…

849. Data-Points-6-Tables (xls file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points-6-tables.xls
     January 01, 2006 - 1 Number of Beneficiaries With at Least One Part A, B, or D Drug Claim for a Biologic of Interest (among continuously enrolled AB FFS population) by Class of Drug and Active Ingredient, 2006-2009 Note: A single period (.) signifies a small cell count (less than 11). Use filters to rank by beneficiary count. …

850. Ebctandcfinal (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/ebctandcfinal.pdf
     June 05, 2012 - AHRQ Evidence-Based Care (EBC) Challenge Terms and Conditions Terms and Conditions: By submitting a product in response to the AHRQ Evidence-Based Care (EBC) Challenge, each team and each team member represents and warrants that:  The team and its members are the sole authors, creators, and owners of the pr…

851. Colon-Cancer-Gene-Profiling Research-Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/colon-cancer-gene-profiling_research-protocol.pdf
     March 13, 2012 - and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses

852. Community Forum Deliberative Methods Demonstration: Evaluating Effectiveness and Eliciting Public Views on Use of Evidence--Executive Summary (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/deliberative-methods-demonstration-executive-131125.pdf
     November 01, 2013 - surveys or focus groups, which generally obtain more top-of-mind—that is, initial and more intuitive—responses … Finally, responses to the question would elicit the public’s values around whether patients and physicians … The panelists’ responses were played back to participants during the third session and served as a basis … • When presented with the deliberative question, many participants’ initial responses showed that

853. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - significant improvement in American College of Rheumatology criteria for 20% improvement (ACR20) responses … 66.3%, and 32.6%, and patients whose symptoms did not respond to previous TNF treatment had ASAS20 responses … patients who received secukinumab 75 mg did not have significant improvements in ASAS20 or ASAS40 responses … Using an observed analysis, patients treated with secukinumab 75 mg had ACR 20/50/70 responses of 66.9%

854. The purpose of our tool is to compile a comprehensive list of questions that may be used to evaluate the quality of non-randomized studies of interventions or exposures (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/reliability-testing-grading-evidence_research.pdf
     May 01, 2012 - completed each of the exercises; subsequently, each pair of reviewers reconciled their independent responses … the 10 exercises; subsequently, the two reviewers—i.e., the ―pair‖—reconciled their independent responses … We assigned a numeric value to each of the domains/strength of evidence responses for each reviewer … Agreement improved to fair (AC1=0.22) among pairs of reviewers for the reconciled responses. … Reconciliation Across Reviewer Pairs We received responses from 8 of the 11 pairs describing the approach

855. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_disposition-comments.pdf
     March 10, 2010 - Comments on draft reviews and the authors’ responses to the comments will be posted publicly on the

856. Disposition of Comments for CERs 155 156 Contast-Induced Nephropathy (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/nephropathy-contrast-induced_disposition-comments.pdf
     January 07, 2016 - Comments on draft reviews and the authors’ responses to the comments are posted for public viewing on … The tables below include the responses by the authors of the review to each comment that was submitted … The responses to comments in this disposition report are those of the authors, who are responsible for

857. Medical Therapies for Children With Autism Spectrum Disorder—An Updaterum Disorder--An Update (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/asd-medical-disposition.pdf
     May 26, 2017 - Comments on draft reviews and the authors’ responses to the comments are posted for public viewing on … The tables below include the responses by the authors of the review to each comment that was submitted … The responses to comments in this disposition report are those of the authors, who are responsible for

858. Hit-Patient-Care Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hit-patient-care_executive.pdf
     June 01, 2012 - Evidence-Based Practice Evidence-based Practice Program The Agency for Healthcare Research and Quality (AHRQ), through its Evidence- based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to imp…

859. Pneumonia-Antibiotic-Treatment Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/pneumonia-antibiotic-treatment_executive.pdf
     November 01, 2014 - risk of bias) that used PK/PD measures to study the impact of different antibiotic dosing on clinical responses

860. Cancer-Drugs-Utilization-Cost Research (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization-cost_research.pdf
     January 01, 2011 - Utilization and cost of anticancer biologic products among Medicare beneficiaries, 2006-2009 Data Points #6Anticancer Biologics From 2006 to 2009, over 800,000 Medicare fee-for-service beneficiaries continuously enrolled in Parts A and B had a claim for an anticancer biologic of interest. Bevacizumab was the m…